The dyslipidemia drugs market is expanding as healthcare systems place greater emphasis on cholesterol management and cardiovascular disease prevention. Increasing diagnosis of lipid disorders and advances in lipid-lowering therapies are creating sustained opportunities for pharmaceutical companies. The Dyslipidemia Drugs Market was valued at US$ 17.63 billion in 2025 and is projected to reach...